Kura Oncology (KURA) Reiterated at Overweight by Cantor Fitzgerald After Webinar on KO-7246
Tweet Send to a Friend
Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Kura Oncology (NASDAQ: KURA).The analyst commented, "Kura and its spin-out ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




